Incyte Corporation, a biopharmaceutical company, has created two new units to better position the organization for future growth in the US and internationally and has named new executives to leads these units. One of these is a US country organization that will lead commercial and medical affairs in the United States. In the future, the company expects to establish other similar country- or regionally based organizations. The other new unit is a Global Product Strategy and Business Development & Licensing (BD&L) unit that will lead global competitive strategies for Incyte’s expanding portfolio beyond Jakafi (ruxolitinib), as well as review business development opportunities.
With these changes, Jim Daly, currently executive vice president and chief commercial officer will leave Incyte later this month. Barry Flannelly, Pharm. D., has been appointed to the newly created position of executive vice president and general manager US, effective immediately. The existing US commercial team, including those responsible for Jakafi, remains intact and will now report into Dr. Flannelly. A newly created position of had of Global Product Strategy and BD&L is expected to be filled in the near future.
Dr. Flannelly has been working in oncology since 1987 and began his career in the pharmaceutical and biotech industry at Rhone-Poulenc Rorer, which later became Sanofi-Aventis. He has since had roles of increasing responsibility at Novartis, Abraxis Oncology, Onyx Pharmaceuticals, and Nektar Therapeutics. During his career, he has held positions in medical affairs, strategic planning, commercial operations, including head of sales and head of marketing, and business development.
Source: Incyte Corporation